234 related articles for article (PubMed ID: 30695050)
21. Phenethyl Isothiocyanate and Cisplatin Co-Encapsulated in a Liposomal Nanoparticle for Treatment of Non-Small Cell Lung Cancer.
Sun M; Shi Y; Dang UJ; Di Pasqua AJ
Molecules; 2019 Feb; 24(4):. PubMed ID: 30813352
[TBL] [Abstract][Full Text] [Related]
22. Evaluation for Synergistic Effects by Combinations of Photodynamic Therapy (PDT) with Temoporfin (mTHPC) and Pt(II) Complexes Carboplatin, Cisplatin or Oxaliplatin in a Set of Five Human Cancer Cell Lines.
Lange C; Bednarski PJ
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30332729
[TBL] [Abstract][Full Text] [Related]
23. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
Budman DR; Calabro A; Kreis W
Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials.
Rajeswaran A; Trojan A; Burnand B; Giannelli M
Lung Cancer; 2008 Jan; 59(1):1-11. PubMed ID: 17720276
[TBL] [Abstract][Full Text] [Related]
25. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
26. Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells.
Mazumder ME; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Nov; 32(11):4851-60. PubMed ID: 23155251
[TBL] [Abstract][Full Text] [Related]
27. Methods for High-throughput Drug Combination Screening and Synergy Scoring.
He L; Kulesskiy E; Saarela J; Turunen L; Wennerberg K; Aittokallio T; Tang J
Methods Mol Biol; 2018; 1711():351-398. PubMed ID: 29344898
[TBL] [Abstract][Full Text] [Related]
28. Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Thibault B; Jean-Claude B
J Ovarian Res; 2017 Apr; 10(1):31. PubMed ID: 28446239
[TBL] [Abstract][Full Text] [Related]
29. Atorvastatin sensitizes human non-small cell lung carcinomas to carboplatin via suppression of AKT activation and upregulation of TIMP-1.
Chen J; Lan T; Hou J; Zhang J; An Y; Tie L; Pan Y; Liu J; Li X
Int J Biochem Cell Biol; 2012 May; 44(5):759-69. PubMed ID: 22305890
[TBL] [Abstract][Full Text] [Related]
30. Dichloroacetate and PX-478 exhibit strong synergistic effects in a various number of cancer cell lines.
Parczyk J; Ruhnau J; Pelz C; Schilling M; Wu H; Piaskowski NN; Eickholt B; Kühn H; Danker K; Klein A
BMC Cancer; 2021 Apr; 21(1):481. PubMed ID: 33931028
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the cytotoxic effects of the combination of cisplatin and flavanol (-)-epicatechin on human lung cancer cell line A549. An isobolographic approach.
Varela-Castillo O; Cordero P; Gutiérrez-Iglesias G; Palma I; Rubio-Gayosso I; Meaney E; Ramirez-Sanchez I; Villarreal F; Ceballos G; Nájera N
Exp Oncol; 2018 Mar; 40(1):19-23. PubMed ID: 29600977
[TBL] [Abstract][Full Text] [Related]
32. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.
Rossi A; Di Maio M
Expert Rev Anticancer Ther; 2016 Jun; 16(6):653-60. PubMed ID: 27010977
[TBL] [Abstract][Full Text] [Related]
33. Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline.
Chu Q; Vincent M; Logan D; Mackay JA; Evans WK;
Lung Cancer; 2005 Dec; 50(3):355-74. PubMed ID: 16139391
[TBL] [Abstract][Full Text] [Related]
34. Topotecan plus ifosfamide in patients with platinum refractory advanced/metastatic non-small cell lung cancer: a phase II trial.
Lorusso V; Gebbia V; Spada M; Guida M; Cassano G; Brunetti C; Germano D; Nettis G; Izzi G; Galetta D; Giampaglia M; Silvestris N; Colucci G
Oncol Rep; 2005 Dec; 14(6):1547-51. PubMed ID: 16273254
[TBL] [Abstract][Full Text] [Related]
35. Rapid fluorescence-based reporter-gene assays to evaluate the cytotoxicity and antitumor drug potential of platinum complexes.
Sandman KE; Marla SS; Zlokarnik G; Lippard SJ
Chem Biol; 1999 Aug; 6(8):541-51. PubMed ID: 10421759
[TBL] [Abstract][Full Text] [Related]
36. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.
Franks SE; Jones RA; Briah R; Murray P; Moorehead RA
BMC Res Notes; 2016 Mar; 9():134. PubMed ID: 26928578
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
[TBL] [Abstract][Full Text] [Related]
38. Taxane-platinum combinations in advanced non-small cell lung cancer: a review.
Rigas JR
Oncologist; 2004; 9 Suppl 2():16-23. PubMed ID: 15161987
[TBL] [Abstract][Full Text] [Related]
39. Self-targeted knockdown of CD44 improves cisplatin sensitivity of chemoresistant non-small cell lung cancer cells.
Quan YH; Lim JY; Choi BH; Choi Y; Choi YH; Park JH; Kim HK
Cancer Chemother Pharmacol; 2019 Mar; 83(3):399-410. PubMed ID: 30515553
[TBL] [Abstract][Full Text] [Related]
40. Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells.
Veschi S; De Lellis L; Florio R; Lanuti P; Massucci A; Tinari N; De Tursi M; di Sebastiano P; Marchisio M; Natoli C; Cama A
J Exp Clin Cancer Res; 2018 Sep; 37(1):236. PubMed ID: 30241558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
